Drugs / Riboflavin
Riboflavin
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | M.V.I.-12 ADULT | — | 1953-02-20 | fda.gov ↗ |
Trials 44
195119521953195419551956195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031203220332034
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04731727 | Jun 2021 → Dec 2026 expected | keratoconus | Kent Wellish MD | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT04481841 | Jul 2020 → Feb 2022 | burning mouth syndrome, mouth mucosa disorder | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02068430 | Nov 2008 → Dec 2015 | corneal ulcer | Stephen Trokel | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT05489510 | Aug 2023 → Dec 2031 | keratoconus | Vishal Jhanji | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT05314738 | Mar 2022 → Aug 2025 overdue | keratoconus | Glaukos Corporation | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01893359 | Aug 2013 → Feb 2015 | astigmatism, hyperopia | Glaukos Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT01582880 | Mar 2012 → Mar 2014 | Stevens-Johnson syndrome, corneal disorder, ocular cicatricial pemphigoid, rheumatoid arthritis +1 | Joseph B. Ciolino, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT00220532 | Jul 2005 → May 2007 | cervical cancer | Sheffield Teaching Hospitals NHS Foundation Trust | Terminated | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT07559149 | Jul 2024 → Feb 2025 | corneal ulcer | Gadjah Mada University | Completed | No outcome recorded |
| Phase 2 | NCT04232800 | Dec 2021 → Aug 2022 | alcohol withdrawal, alcohol-related disorders, nutritional disorder | Oregon Health and Science University | Unknown | No outcome recorded |
| Phase 2 | NCT03552016 | Oct 2018 → Oct 2029 | myopia | University of Missouri-Columbia | Suspended | No outcome recorded Stop: Business |
| Phase 2 | NCT02622386 | Aug 2016 → Apr 2020 | psoriasis | University of Michigan | Completed | No outcome recorded |
| Phase 2 | NCT02446977 | Mar → Dec 2015 | ischemic stroke | Castillo, José, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT02276989 | Dec 2014 → Jan 2016 | chronic pain syndrome | Georgetown University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02762253 | Sep 2012 → Apr 2016 | keratoconus | Nvision Laser Eye Centers | Terminated | No outcome recorded |
| Phase 2 | NCT00963131 | Dec 2004 → Dec 2008 | central serous chorioretinopathy | Prince of Songkla University | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT05255016 | Mar 2022 → Nov 2023 | corneal ulcer | Peschke GmbH | Unknown | No outcome recorded |
| Phase 2/3 | NCT05255107 | Mar 2022 → Nov 2023 | corneal ulcer | Peschke GmbH | Unknown | No outcome recorded |
| Phase 2/3 | NCT04787471 | May 2021 → Jul 2029 expected | corneal neovascularization | Price Vision Group | Recruiting | No outcome recorded |
| Phase 2/3 | NCT00143702 | Aug 2001 → Aug 2006 | lactic acidosis | University of British Columbia | Completed | No outcome recorded |
| Phase 311 trials · 2 met primary · 2 missed | ||||||
| Phase 3 | NCT07135167 | Aug 2025 → Nov 2028 expected | Down syndrome, keratoconus, pellucid marginal degeneration | Woolfson Eye Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT06100952 | Nov 2023 → Feb 2026 | keratoconus | Epion Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT04631484 | Nov 2020 → May 2024 | brain injury | POLYSAN Scientific & Technological Pharmaceutical Company | Completed | Met primary |
| Phase 3 | NCT04097730 | Sep 2020 → May 2024 | keratitis | Thomas M. Lietman | Completed | Missed primary |
| Phase 3 | NCT03442751 | Apr 2018 → Nov 2019 | keratoconus | Glaukos Corporation | Completed | Met primary |
| Phase 3 | NCT03426553 | Jan → Sep 2018 | cancer-related condition, hematologic disorder | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Completed | No outcome recorded |
| Phase 3 | NCT01972854 | Nov 2013 → Mar 2016 | keratoconus | Glaukos Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT01643226 | Jul 2012 → Jul 2015 | keratoconus | Glaukos Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01344187 | Jul 2012 → Jun 2015 | keratoconus | Glaukos Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01398852 | Dec 2010 → Jul 2012 | keratoconus | Topcon Medical Systems, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00116493 | Apr 2004 → May 2007 | anemia | Johns Hopkins Bloomberg School of Public Health | Completed | Missed primary |
| Phase 45 trials · 1 met primary | ||||||
| Phase 4 | NCT07592897 | Jun → Nov 2026 expected | — | University of Sao Paulo | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07629557 | May 2026 → Sep 2027 expected | keratoconus | Glaukos Corporation | Recruiting | No outcome recorded |
| Phase 4 | NCT02415777 | Oct 2014 → Jul 2015 | — | Daewoong Pharmaceutical Co. LTD. | Completed | Met primary |
| Phase 4 | NCT01485211 | Jan 2010 → Nov 2011 | keratoconus | Instituto de Olhos de Goiania | Completed | No outcome recorded |
| Phase 4 | NCT00202228 | Jul 2002 → Oct 2008 | AIDS, lactic acidosis, lipodystrophy | Queen's University | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT04062435 | Dec 2019 → Mar 2020 | keratoconus | Luzerner Kantonsspital | Completed | No outcome recorded |
| — | NCT02235337 | Sep 2014 → Aug 2015 | — | University of Virginia | Completed | No outcome recorded |
| — | NCT01789333 | Sep 2010 → Dec 2022 | corneal ectasia, keratoconus | Stephen Trokel | Withdrawn | No outcome recorded |
| — | NCT01474486 | Apr 2010 → Feb 2016 | cardiomyopathy, congestive heart failure | Phoenix VA Health Care System | Completed | No outcome recorded |
| — | NCT02456961 | Jan 2010 → Dec 2014 | keratoconus | Ufa Eye Research Institute | Completed | No outcome recorded |
| — | NCT00037063 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| — | NCT00031057 | ? → Mar 2003 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT01307527 | — | brittle cornea syndrome | Hadassah Medical Organization | Unknown | No outcome recorded |
| Comparator or background therapy46 trials | ||||||
| Phase 0 | NCT05907850 Comparator | Jun 2023 → May 2024 | — | Steven Moore | Completed | No outcome recorded |
| Phase 0 | NCT03432572 Comparator | Jun 2018 → Jun 2020 | — | Texas Tech University Health Sciences Center | Completed | No outcome recorded |
| Phase 1 | NCT04667572 Background | Feb 2021 → Aug 2024 | corneal degeneration, corneal ectasia, keratoconus, pellucid marginal degeneration | Cornea Associates of Texas | Completed | No outcome recorded |
| Phase 1 | NCT04177082 Background | Jan 2020 → May 2022 | corneal degeneration, corneal ectasia, keratoconus, pellucid marginal degeneration | Cornea Associates of Texas | Completed | No outcome recorded |
| Phase 1 | NCT03918408 Background | Sep 2019 → Dec 2029 expected | corneal ectasia, keratitis, keratoconus | Pacific Clear Vision Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT02009709 Comparator | Oct 2013 → Jan 2017 | corneal ectasia, keratoconus | Robert Mack, M.D. | Unknown | No outcome recorded |
| Phase 1/2 | NCT02863809 Background | Mar 2017 → Jun 2021 | keratinization disease | Joseph B. Ciolino, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT02507362 Background | Aug 2014 → Dec 2015 | keratoconus | Tehran University of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT02883478 Comparator | Aug 2012 → Aug 2016 | corneal ectasia, keratoconus | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04240457 Background | Jul 2020 → Feb 2023 | corneal ectasia, keratoconus | Arbor Center for Eye Care | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04213885 Background | May 2020 → Aug 2024 | corneal ectasia, keratitis, keratoconus | Eye Specialists of Indiana | Completed | No outcome recorded |
| Phase 2 | NCT06260072 Comparator | Feb 2020 → Dec 2025 overdue | — | University of Virginia | Recruiting | No outcome recorded |
| Phase 2 | NCT04094090 Background | Oct 2019 → Oct 2029 expected | corneal ectasia, keratoconus, pellucid marginal degeneration | Goodman Eye Center | Recruiting | No outcome recorded |
| Phase 2 | NCT02324153 Background | Mar 2017 → Jun 2019 | delirium | Johns Hopkins University | Completed | Missed primary |
| Phase 2 | NCT02772237 Comparator | Aug 2016 → Dec 2018 | — | University of Virginia | Unknown | No outcome recorded |
| Phase 2 | NCT02514200 Background | Mar 2014 → Oct 2019 | keratoconus | Umeå University | Unknown | No outcome recorded |
| Phase 2 | NCT01704196 Comparator | Apr 2013 → Aug 2014 | cocaine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT01325298 Comparator | Mar 2011 → Mar 2014 | corneal ectasia, keratoconus | Mercy Center for Corrective Eye Surgery | Unknown | No outcome recorded |
| Phase 2 | NCT01143389 Comparator | May 2010 → May 2017 | corneal ectasia, keratoconus | Price Vision Group | Completed | No outcome recorded |
| Phase 2/3 | NCT07841470 Background | Oct 2025 → Dec 2030 expected | corneal ectasia, keratoconus | Price Vision Group | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03922542 Background | Apr 2019 → Jun 2026 | corneal ectasia, keratoconus | Price Vision Group | Completed | No outcome recorded |
| Phase 2/3 | NCT01081561 Comparator | Jan 2009 → Dec 2020 | corneal ectasia, keratoconus | Yaron S. Rabinowitz M.D. | Unknown | No outcome recorded |
| Phase 2/3 | NCT00679666 Comparator | Apr 2008 → Apr 2010 | corneal ectasia, keratoconus | Ohio State University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT00435799 Comparator | Feb 2007 → Jan 2009 | keratoconus | Ullevaal University Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT00064753 Background | May 2002 → Oct 2011 | cardiovascular disorder, chronic kidney disease | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | Missed primary |
| Phase 3 | NCT07124910 Background | Aug 2025 → Nov 2028 expected | corneal ectasia, keratoconus, pellucid marginal degeneration | Woolfson Eye Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT05027295 Comparator | Jul 2021 → Jul 2025 | corneal ectasia, keratoconus | Cornea and Laser Eye Institute | Unknown | No outcome recorded |
| Phase 3 | NCT04905108 Comparator | Jun 2021 → Jun 2025 | corneal ectasia, keratoconus | Cornea and Laser Eye Institute | Unknown | No outcome recorded |
| Phase 3 | NCT04897503 Comparator | Apr 2021 → Jun 2025 | corneal ectasia, keratoconus | Cornea and Laser Eye Institute | Unknown | No outcome recorded |
| Phase 3 | NCT03198507 Background | Jun 2017 → Oct 2018 | Helicobacter pylori infectious disease, dyspepsia | RedHill Biopharma Limited | Completed | Met primary |
| Phase 3 | NCT03187912 Comparator | Sep 2016 → Mar 2020 | keratoconus | Medical University of Vienna | Completed | No outcome recorded |
| Phase 3 | NCT02769494 Comparator | Mar → Dec 2016 | Crohn disease, ulcerative stomatitis | Xijing Hospital of Digestive Diseases | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT02095730 Comparator | May 2014 → May 2016 | corneal disorder | Crowd Health Research, LTD | Unknown | No outcome recorded |
| Phase 3 | NCT01643252 Comparator | Jul 2012 → ? | corneal ectasia | Glaukos Corporation | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT01464268 Comparator | Nov 2011 → Dec 2024 | corneal ectasia, keratoconus | Cornea and Laser Eye Institute | Unknown | No outcome recorded |
| Phase 3 | NCT01295450 Comparator | Apr → Aug 2011 | eating disorder | MDCPharma Produtos Farmaceuticos LTDA | Unknown | No outcome recorded |
| Phase 3 | NCT01398839 Background | Dec 2010 → Jul 2012 | corneal ectasia | Topcon Medical Systems, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01190306 Background | Aug 2010 → Dec 2011 | keratoconus | Topcon Medical Systems, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT01152541 Comparator | Jun 2010 → Dec 2024 | corneal ectasia, keratoconus | Cornea and Laser Eye Institute | Unknown | No outcome recorded |
| Phase 3 | NCT01112072 Comparator | Apr 2010 → Dec 2024 | corneal ectasia, keratoconus | Cornea and Laser Eye Institute | Unknown | No outcome recorded |
| Phase 3 | NCT00674661 Comparator | Dec 2007 → Nov 2011 | corneal ectasia | Glaukos Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00647699 Comparator | Dec 2007 → Apr 2011 | keratoconus | Glaukos Corporation | Completed | No outcome recorded |
| Phase 4 | NCT04427956 Comparator | May 2017 → Nov 2024 | keratoconus | Region Skane | Completed | No outcome recorded |
| Phase 4 | NCT02620345 Background | Jan 2010 → Oct 2015 | benign neoplasm of corpus uteri | Trieu, Nguyen Thi, M.D. | Completed | No outcome recorded |
| — | NCT05881187 Comparator | Jun 2023 → Apr 2024 | keratitis | Sohag University | Unknown | No outcome recorded |
| — | NCT00912509 Comparator | May 2009 → Jun 2013 | keratitis | Price Vision Group | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-10-07 | Glaukos Corporation | Results Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus glaukos.com ↗
The long-term follow-up results demonstrated durable efficacy and a favorable long-term safety profile through three years following a single Epioxa treatment, with no additional intervention during the extension period. |
| 2025-10-20 | Glaukos Corporation | Regulatory Glaukos Announces FDA Approval of Epioxa™ glaukos.com ↗
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U.S. Food and Drug Administration (FDA) approved its Epioxa™ HD / Epioxa™ (“Epioxa”) New Drug Application (NDA). |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-10-07 | Glaukos Corporation | Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus glaukos.com ↗ |
| 2025-10-20 | Glaukos Corporation | Glaukos Announces FDA Approval of Epioxa™ glaukos.com ↗ |
| 2010-01-12 | Eisai Inc. | Eisai Introduces New Chocola BB Series Pharmaceutical Product “Chocola BB® Royal T” Vitamin B2, Royal Jelly and Taurine Containing Tablets Alleviate Symptoms of Daily Fatigue eisai.com ↗ |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 90 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Riboflavin | “with daily multivitamins [vitamin A (300 microg, as retinol palmitate), vitamin E (6 mg tocopherol equivalents), vitamin B-12 (0.9 microg), vitamin C (15 mg), riboflavin (0.5...” PMID 19535425 ↗ Jun 200985“Randomized Clinical Trial to Investigate Whether Administration of CBG000592 (Riboflavin/Vitamin B2) in Patients With Acute Ischemic Stroke Causes a Reduction of...” NCT02446977 ↗ “riboflavin (Peschke-TE 0.25% ophthalmic solution or Peschke-L 0.23% ophthalmic solution) administered in conjunction with the UVA light as a photosensitizer” NCT05489510 ↗ “120 mg of active drug and 100mg of riboflavin daily for 11 weeks or matching placebo containing 100mg of riboflavin daily for 11 weeks.” NCT01704196 ↗ “Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine” NCT01474486 ↗ “The intervention to be studied will be an alternative application of riboflavin drops in the inferior fornix.” NCT04062435 ↗ “Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea.” NCT04240457 ↗ “Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea” NCT03918408 ↗ “Thiamin Mononitrate 1.5 mg/day Riboflavin 1.7 mg/day Niacinamide 18 mg/day” NCT02620345 ↗ “One 50mg Riboflavin tablet to be taken once daily to maintain the blind” NCT03198507 ↗ “applying riboflavin (Vitamin B2 eye drops) to the eye” NCT07135167 ↗ |
| Known as | Peschke Riboflavin 0.25% Transepithelial Solution | “riboflavin (Peschke Riboflavin 0.25% Transepithelial Solution) administered in conjunction with the UV-A light as a photosensitizer.” NCT05255016 ↗ |
| Known as | Peschke-L | “riboflavin (Peschke-TE 0.25% ophthalmic solution or Peschke-L 0.23% ophthalmic solution) administered in conjunction with the UVA light as a photosensitizer” NCT05489510 ↗ |
| Known as | PESCHKE-L Solution | “PESCHKE-L Solution is a riboflavin 5'-phosphate 0.23% ophthalmic solution that functions as a photosensitizer and is indicated for use with the PXL Platinum 330 Illumination System.” NCT05255107 ↗ |
| Known as | Peschke-TE | “riboflavin (Peschke-TE 0.25% ophthalmic solution or Peschke-L 0.23% ophthalmic solution) administered in conjunction with the UVA light as a photosensitizer” NCT05489510 ↗ |
| Known as | Riboflavin 100mg capsules | “Riboflavin 100mg capsules” NCT05907850 ↗ |
| Known as | Riboflavin sodium phosphate | “Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg,...” NCT01295450 ↗ |
| Known as | Riboflavin+UV RBC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03426553 ↗ |
| Known as | Riboflavin/Dextran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01152541 ↗ |
| Known as | VibeX | “Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by irradiation with the KXL system” NCT01643252 ↗1“The cornea will receive 5 drops of VibeX (0.12% riboflavin ophthalmic solution).” NCT01972854 ↗ |
| Known as | Vitamin B2 | “Deficiencies in thiamine (vitamin B1) and riboflavin (vitamin B2) have been implicated as cofactors in producing hyperlactatemia and lactic acidosis in NRTI-treated patients.” NCT00031057 ↗6“Riboflavin (Vitamin B2) 400 mg capsule taken daily for 12 weeks.” NCT02622386 ↗ “applying riboflavin (Vitamin B2 eye drops) to the eye” NCT07135167 ↗ “applying riboflavin (Vitamin B2 eye drops) to the eye” NCT07124910 ↗ “riboflavin, also known as vitamin B2” NCT05907850 ↗ “Vitamin B2 (Riboflavin): 1.5 mg” NCT00064753 ↗ |
| Modality | Other / unclassified | “giving a low dose of the vitamins folic acid and riboflavin” NCT00220532 ↗ |
| Route | Oral | “every patient receives high-dose oral vitamin B1 and B2 therapy for 4 weeks.” NCT00031057 ↗ |